vedolizumab

FDA Drug Profile — ENTYVIO Pen, ENTYVIO, Entyvio

vedolizumab is listed in the FDA National Drug Code directory with 3 NDC codes, marketed under brand names including ENTYVIO Pen, ENTYVIO, Entyvio. Available dosage forms: injection, solution, injection, powder, lyophilized, for solution.

Drug details

Generic Name
vedolizumab
Brand Names
ENTYVIO Pen, ENTYVIO, Entyvio
Application Number
BLA761133
Sponsor
Takeda Pharmaceuticals America, Inc.
NDC Codes
3
Dosage Forms
INJECTION, SOLUTION, INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Routes
SUBCUTANEOUS, INTRAVENOUS
Active Ingredients
VEDOLIZUMAB

Indications and Usage

1 INDICATIONS AND USAGE ENTYVIO is indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC). moderately to severely active Crohn's disease (CD). ENTYVIO is an integrin receptor antagonist indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC). ( 1 ) moderately to severely active Crohn's disease (CD). ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.